1 Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
SLAS Discov. 2017 Apr;22(4):360-365. doi: 10.1177/1087057116673181. Epub 2016 Oct 8.
Monoacylglycerol acyltransferase (MGAT) activity catalyzes the synthesis of diacylglycerol (DAG) from fatty acyl-CoA and monoacylglycerol as substrates. It is important for the resynthesis of triacylglycerol (TAG) in the intestine. In the present study, we developed a MGAT enzymatic assay of human intestinal microsomes using a high-throughput mass spectrometry (MS)-based detection system. After screening with small-molecular-weight libraries for compounds exhibiting inhibitions against DAG and the consequent TAG syntheses, we identified multiple compounds that specifically inhibit intestinal MGAT activity. The inhibitory activities of these compounds were correlated to those determined using a recombinant human MGAT2 enzyme. An aryl-sulfonamide compound T1 showed potent inhibitory activity toward human intestinal MGAT and recombinant human MGAT2, with selectivity over MGAT3. This high-throughput MS-based assay provides a novel platform for the discovery of DAG or TAG synthesis inhibitors. The identified aryl-sulfonamide compound T1 is a promising starting compound for optimization studies of inhibitors with selectivity toward MGAT2.
单酰甘油脂肪酶 (MGAT) 活性催化二酰基甘油 (DAG) 的合成,其反应底物为脂肪酸辅酶 A 和单酰甘油。这对于肠道中三酰基甘油 (TAG) 的再合成非常重要。在本研究中,我们使用高通量质谱 (MS) 为基础的检测系统开发了一种人肠微粒体 MGAT 酶促测定法。经过对小分子文库化合物的筛选,发现了多种能抑制 DAG 并阻止 TAG 合成的化合物,这些化合物能特异性抑制肠道 MGAT 活性。这些化合物的抑制活性与用重组人 MGAT2 酶测定的结果相关。一种芳基磺酰胺化合物 T1 对人肠道 MGAT 和重组人 MGAT2 显示出强烈的抑制活性,对 MGAT3 具有选择性。这种基于高通量 MS 的测定法为 DAG 或 TAG 合成抑制剂的发现提供了一个新的平台。鉴定出的芳基磺酰胺化合物 T1 是一种有前途的起始化合物,可用于对 MGAT2 具有选择性的抑制剂的优化研究。